Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure

Annals of Hepatology

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Kobashi Margáin, Ramón A ^a   Gavilanes Espinar, Juan G ^a   Gutiérrez Grobe, Ylse ^a   Gutiérrez Jiménez, Ángel A ^a   Chávez Tapia, Norberto ^a   Ponciano Rodríguez, Guadalupe ^b   Uribe, Misael ^a   Sánchez, Nahum Méndez ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acute liver failure; Acute on chronic liver failure; Hepatic encephalopathy; Molecular adsorbent recirculating system

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA1 GLYCOPROTEIN; AMMONIA; BENZODIAZEPINE; BILE ACID; BILIRUBIN; COPPER; CREATININE; DIAZEPAM; FATTY ACID; HEPARIN; INTERLEUKIN 6; TRANSFERRIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE LIVER FAILURE; ALBUMIN DIALYSIS; ANION EXCHANGE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BRAIN PERFUSION; CHOLESTASIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DETOXIFICATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; HEALTH STATUS; HEMODIALYSIS; HEMOFILTRATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOTENSION; INTOXICATION; INTRACRANIAL PRESSURE; KIDNEY BLOOD FLOW; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; MEMBRANE PERMEABILITY; OUTCOME ASSESSMENT; PROCESS DESIGN; PRURITUS; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEM ANALYSIS; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 79961197589     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31611-4     Document Type: Review

References (39)

1. Keeffe E. Hepatic failure and liver transplantation. In: Goldman. Cecil Medicine. Cap. 158. 23th. Ed. Saunders; 2007, p. 1147-52.
2. Sen S, Williams R, Jalan R. Emerging indications for albumindialysis. Am J Gastroenterol 2005; 100: 468-75.
3. Pless G. Artificial and bioartificial liver support. Organogenesis 2007; 3(1): 20-4.
4. Stevens C. Liver Support Systems. Up to date 2008.
5. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H,Schmidt R. A new procedure for the removal of protein bound drugs and toxins. SAIO J 1993; 39: 621-5.
6. Mitzner ST, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-S82.
7. Awad SS, Swaniker F, Bartlett RH. Results of a phase I Trial evaluating a liver support device utilizing albumin dialysis.Surgery 2001; 130: 354-62.
8. Stange J, Mitzner S. A carrier-mediated transport oftoxins in a Hybrid membrane. Safety barrier between a patient blood and bioartificial liver. Int J Artif Organs 1996; 19: 677-91.
9. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dyalisis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
10. Saliba F. The molecular adsorbent recirculating system(MARS) in the intensive care unit: a rescue therapy with hepatic failure. Critical Care 2006; 10(1): 186-9.
11. Sen S, Rose C, Ytrebø LM, et al. Effect of albumin dialysison intracraneal pressure increase in pigs with acute liver failure: A randomized study. Critical Care Med 2006; 34: 158-64.
12. Sen S, Ytrebø LM, Rose C, et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein bounddrugs. Intensive Care Med 2004; 30: 496-501.
13. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-19.
14. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the mo-lecular adsorbent recirculating system and Prometheusdevices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2007; 10: 14.
15. Donati G, Piscaglia F, Coli L, Silvagni E, Righini R, Stefoni S, et al. Acute systemic, splachnic and renal hemodynamicchanges Induced by molecular adsorbent recirculating sys-tem (MARS). Treatment in patients with end-stage cirrhosis. Aliment Pharmacol Ther 2007; 26: 717-26.
16. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, et al. Extracorporeal albumin dyalisis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.
17. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposedacute liver injury: A prospective, controlled study. Hepatology 2002; 36: 949-58.
18. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al. Improvement of multiple organ functions inhepatorenal syndrome during albumin dyalisis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-22.
19. Camus C, Lavoué S, Gacouin A, et al. Molecular adsorbent recirculating system dialysis patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006; 32: 1817-25.
20. Wagholikar GD, Lee KH, Pandey D, et al. Pre-transplant optimization by molecular adsorbent recirculating systemin patients with severely decompensated chronic liver disease. Indian J Gastroenterol 2007; 26: 110-2.
21. Choi JY, Bae SH, Yoon SK, et al. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation-a pilot study. Liver Int 2005; 25: 740-5.
22. Tan HK, Lim JS, Tan CK, et al. MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report. Liver Int 2003; 23(Suppl. 3): 52-60.
23. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure a systematic review. JAMA 2003; 2: 217-22.
24. Lemoine M, Revaux A, Francoz C, et al. Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus. World J Gastroenterol 2008; 14: 6572-4.
25. Wu BF, Wang MM. Molecular adsorbent recirculating sys-tem in dealing with maternal Amanita poisoning during thesecond pregnancy trimester: a case report. Hepatobilia-ry Pancreat Dis Int 2004; 3(1): 151-4.
26. Ilonen I, Koivusalo A, Repo H, Höckerstedt R, Isoniemi H. Cytokine profiles in acute liver failure treated with albumin dialysis. Artif Organs 2008; 32: 51-60.
27. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed liver injury: possible impactof albumin dialysis on hospitalization costs. Liver Int 2003; 23: 61-5.
28. Kantola T, Mäklin S, Koivusalo AM, et al. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol 2010; 16(18): 2227-34.
29. Jalan R, Williams R. Improvement in cerebral perfusion after MARS therapy: further clues about the pathogenesis ofhepatic encephalopathy? Liver Transplantation 2001; 7(8): 713-5.
30. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol 2010; 16 (27): 3347-57.
31. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalo-pathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.
32. Schmidt LE, Svendsen LB, Sorensen VB, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a singletreatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transplant 2001; 7(8): 709-12.
33. Mora JM, Olmedo R, Curiel E, et al. MARS (molecular adsorbent recirculating system) como asistencia extracorpórea hepática en el fracaso hepático agudo grave de etiología enólica. Med Intensiva 2006; 30(8): 402-6.
34. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.
35. Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, et al. Acute liver failure and the molecular adsorbents recirculating system: Early experience in a tertiary care hospital in Mexico City. Ann Hepatol 2004; 3(4): 164-6.
36. Schmidt LE, Svendsen LB, Sorensen VB, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liv Transplant 2001; 7(8): 709-12.
37. Mora JM, Olmedo R, Curiel E, et al. MARS (molecular adsor-bent recirculating system) como asistencia extracorpórea hepática en el fracaso hepático agudo grave de etiología enólica. Med Intens 2006; 30(8): 402-6.
38. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomizedcontrolled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.
39. Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, et al. Acute liver failure and the molecular adsorbents recirculating system: Early experience in a tertiary care hospital in Mexico City. Ann Hepatol 2004; 3(4): 164-6.